Format

Send to

Choose Destination
J BUON. 2019 Nov-Dec;24(6):2267-2272.

A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer.

Author information

1
Department of Thoracic Surgery, Cancer Hospital of China Medical University, Shenyang 110042, China.

Abstract

PURPOSE:

To explore the clinical efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced non-small cell lung cancer (NSCLC).

METHODS:

A total of 64 patients with middle and advanced NSCLC were randomly divided into the control group (n=32) and observation group (n=32). The patients in control group received paclitaxel monotherapy, while those in the observation group were treated with recombinant human endostatin combined with apatinib mesylate. The short-term efficacy, the lung function and levels of immunoglobulin and T lymphocyte subsets before and after treatment and the adverse drug reactions of patients were compared between the two groups. All patients were followed up for 5 years, and the survival rate in the two groups was observed.

RESULTS:

The short-term efficacy and lung function in observation group were better than those in control group (p<0.05). Compared with those in the control group, the levels of immunoglobulin G (IgG), IgA, IgM, cluster of differentiation 3+ (CD3+), CD4+ and CD4+/CD8+ were increased, while the CD8+ level was lowered in the observation group (p<0.05). The rate of adverse drug reactions in the observation group was lower than that in the control group (p<0.05). The 5-year survival rate was significantly higher in the observation group than that in the control group (p<0.05).

CONCLUSION:

Recombinant human endostatin combined with apatinib mesylate achieves a better therapeutic effect in the treatment of middle and advanced NSCLC, with improved immune resistance of patients and less side effects. Therefore, it is worthy of popularization and application in clinical practice.

PMID:
31983093
Free full text

Supplemental Content

Full text links

Icon for Zerbinis, Medical Publications
Loading ...
Support Center